IARTIntegra LifeSciences Holdings Corporation
Is the price fair?
A demanding price: priced for +13% a year vs +2% a year delivered and at the top of its own P/E range.
Priced for ~13% a year FCF growth. The price demands more than its three-year revenue growth of 2% a year, priced for acceleration.
Expensive vs its own history: P/E 100.5 vs a 52.2 median over 31 quarters (+92% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What IART's price assumes
Today's price asks for 13% free cash flow growth a year; over the last three years Integra LifeSciences Holdings Corporation delivered −45%, so the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.8%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; the business has delivered −45% a year over the last three.
- Price / book
- 0.89
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 0.89
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 21.4
- EV / salestoday's price, trailing year to Jun 30, 2026
- 0.85
- Free cash flow, trailing twelve months
- $26M
- Market capitalisation77.8 million shares, counted Jul 28, 2026
- $926M
- 3-year revenue growth
- +2.2%
- 3-year free cash flow growth
- −45%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Medical Devices
Ranks #14 of 50 by RyuScore